The mean PFS was also significantly better in those with CD133+ tumours, with a mean of 158 month (95% CI, 150–167) vs. 139 months (95% CI, 120–159) in those CD133−tumours (p = 0.014). This evidence concerns the gene PROM1 and neoplasm.